MetaVia has completed the dosing of the first participant in Part 3 of its Phase I trial for DA-1726, an investigational therapy targeting obesity and related cardiometabolic conditions. The study is focused on assessing higher-dose regimens aimed at improving treatment effectiveness while maintaining safety and tolerability.

DA-1726 is a next-generation oxyntomodulin analogue designed to act as a dual agonist of GLP-1 and glucagon receptors. By targeting both pathways, the therapy aims to promote weight loss through appetite suppression and increased energy expenditure, while also delivering metabolic benefits such as improved glycaemic control and potential liver health improvements.

Earlier trial data have shown encouraging outcomes, including notable weight reduction, decreased waist circumference and positive effects on blood sugar levels, all supported by a favourable safety profile. The ongoing Part 3 trial is structured to explore one-step and two-step dose escalation strategies over a 16-week period, with the goal of reaching optimal therapeutic doses more efficiently compared to existing treatments.

The study is expected to enrol 40 obese but otherwise healthy adults, divided into two cohorts to evaluate different titration approaches. Researchers will monitor key safety indicators alongside pharmacokinetic and pharmacodynamic responses, while also assessing changes in body weight, body mass index, lipid levels and other cardiometabolic markers.

Preclinical findings suggest that DA-1726 may offer advantages over currently available therapies by delivering comparable or improved weight loss outcomes while preserving lean body mass and enhancing lipid metabolism. These characteristics position the drug as a promising candidate in the evolving landscape of obesity and metabolic disease treatments.

With further data anticipated later in 2026, MetaVia continues to focus on advancing DA-1726 as a differentiated therapeutic option, aiming to address growing global demand for more effective and convenient obesity treatments.